Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OCUL
stocks logo

OCUL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
16.28M
-4.69%
-0.319
+10.03%
14.22M
+32.95%
-0.340
-10.53%
15.12M
+12.36%
-0.343
-11.97%
Estimates Revision
The market is revising Downward the revenue expectations for Ocular Therapeutix, Inc. (OCUL) for FY2025, with the revenue forecasts being adjusted by -1.65% over the past three months. During the same period, the stock price has changed by -8.60%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.65%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.37%
In Past 3 Month
Stock Price
Go Down
down Image
-8.60%
In Past 3 Month
Wall Street analysts forecast OCUL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCUL is 22.70 USD with a low forecast of 18.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast OCUL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCUL is 22.70 USD with a low forecast of 18.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.430
sliders
Low
18.00
Averages
22.70
High
31.00
Current: 12.430
sliders
Low
18.00
Averages
22.70
High
31.00
LifeSci Capital
NULL
to
Outperform
initiated
$55
2025-12-03
New
Reason
LifeSci Capital
Price Target
$55
2025-12-03
New
initiated
NULL
to
Outperform
Reason
LifeSci Capital initiated coverage of Oculis with an Outperform rating and $55 price target.
Clear Street
Buy
maintain
$18 -> $21
2025-11-04
Reason
Clear Street
Price Target
$18 -> $21
2025-11-04
maintain
Buy
Reason
Clear Street raised the firm's price target on Ocular Therapeutix to $21 from $18 and keeps a Buy rating on the shares after the company reported Q3 results and announced that SOL-R, the second registrational trial of AXPAXLI in wet age-related macular degeneration, has completed target randomization. Ocular's clinical trial execution for AXPAXLI has "continued to impress," the analyst tells investors.
TD Cowen
Buy
upgrade
$14 -> $20
2025-10-30
Reason
TD Cowen
Price Target
$14 -> $20
2025-10-30
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Ocular Therapeutix to $20 from $14 and keeps a Buy rating on the shares. The firm updated its model as they and key opinion leaders are highly optimistic about Axpaxli's robust use in wAMD with a differentiated superiority label, and Cowen's $1B peak estimate is conservative.
JMP
Jonathan Wolleben
Outperform
maintain
$20 -> $29
2025-10-01
Reason
JMP
Jonathan Wolleben
Price Target
$20 -> $29
2025-10-01
maintain
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben raised the firm's price target on Ocular Therapeutix to $29 from $20 and keeps an Outperform rating on the shares. New details on a derisked pivotal program in Nonproliferative Diabetic Retinopathy allows value to be ascribed to the potential blockbuster opportunity while the wet AMD pivotal readouts will drive near-term value creation, the analyst tells investors in a research note.
Chardan
NULL
to
Buy
initiated
$21
2025-09-15
Reason
Chardan
Price Target
$21
2025-09-15
initiated
NULL
to
Buy
Reason
Chardan initiated coverage of Ocular Therapeutix with a Buy rating and $21 price target. The company's lead Axpaxli program is slowly released over several months and has a potential to significantly reduce anti-VEGF treatment burden for patients with wet age-related macular degeneration and non-proliferative diabetic retinopathy, the analyst tells investors in a research note.
Scotiabank
Outperform
to
NULL
downgrade
$22 -> $20
2025-08-06
Reason
Scotiabank
Price Target
$22 -> $20
2025-08-06
downgrade
Outperform
to
NULL
Reason
Scotiabank lowered the firm's price target on Ocular Therapeutix to $20 from $22 and keeps an Outperform rating on the shares. While the read out for the SOL-R trial is now further than expected, the firm continues to remain confident in the wet age-related macular degeneration, wAMD, program and believes the company's pursuit of a superiority label with Eylea can set up Axpaxli for commercial success, the analyst tells investors. The firm updated its price target to reflect the updated timeline expectations for Axpaxili.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ocular Therapeutix Inc (OCUL.O) is -9.12, compared to its 5-year average forward P/E of -11.08. For a more detailed relative valuation and DCF analysis to assess Ocular Therapeutix Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.08
Current PE
-9.12
Overvalued PE
3.58
Undervalued PE
-25.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.59
Undervalued EV/EBITDA
-11.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.46
Current PS
0.00
Overvalued PS
24.90
Undervalued PS
4.02
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2312.47% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OCUL News & Events

Events Timeline

(ET)
2025-11-24
07:21:29
Ocular Therapeutix reports first patient enrolled in HELIOS-3 trial
select
2025-11-07 (ET)
2025-11-07
07:10:49
Ocular Therapeutix announces inducement grant in accordance with Nasdaq listing regulations.
select
2025-11-04 (ET)
2025-11-04
07:39:19
Ocular Therapeutix reaches goal of randomizing 555 participants in SOL-R study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-25Benzinga
HC Wainwright & Co. Affirms Buy Rating for Ocular Therapeutix, Keeps $19 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
6.5
11-20NASDAQ.COM
Wall Street Analysts Predict Ocular Therapeutix (OCUL) May Rise by 82.48%: Important Insights Before You Invest

  • Stock Performance and Analyst Predictions: Ocular Therapeutix (OCUL) shares have risen 6.7% recently, with Wall Street analysts projecting a mean price target of $22.08, suggesting an 82.5% potential upside from the current price of $12.1.

  • Skepticism Towards Price Targets: While analysts show strong agreement on OCUL's earnings prospects, relying solely on price targets for investment decisions is cautioned against, as they can often be misleading and overly optimistic due to business incentives.

  • Earnings Estimate Revisions: There has been a positive trend in earnings estimate revisions for OCUL, with a 2.5% increase in the Zacks Consensus Estimate over the past month, indicating a potential for stock price growth.

  • Zacks Rank and Future Outlook: OCUL holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which, along with its strong earnings track record, suggests a favorable outlook for the stock's near-term performance.

[object Object]
Preview
9.5
11-04NASDAQ.COM
Ocular Therapeutix Inc. Reports Wider Q3 Loss, Falls Short of Expectations

  • Earnings Report: Ocular Therapeutix Inc. reported a third-quarter loss of $69.42 million, or -$0.38 per share, which is an increase from last year's loss of $36.49 million, or -$0.22 per share.

  • Analyst Expectations: The company's earnings fell short of analysts' expectations, which had predicted a loss of -$0.35 per share.

  • Revenue Decline: Revenue for the quarter decreased by 5.8%, totaling $14.54 million compared to $15.43 million in the same period last year.

  • GAAP Earnings Summary: Key figures for Ocular Therapeutix include a loss of $69.42 million, an EPS of -$0.38, and revenue of $14.54 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ocular Therapeutix Inc (OCUL) stock price today?

The current price of OCUL is 12.43 USD — it has increased 8.46 % in the last trading day.

arrow icon

What is Ocular Therapeutix Inc (OCUL)'s business?

Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.

arrow icon

What is the price predicton of OCUL Stock?

Wall Street analysts forecast OCUL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCUL is 22.70 USD with a low forecast of 18.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ocular Therapeutix Inc (OCUL)'s revenue for the last quarter?

Ocular Therapeutix Inc revenue for the last quarter amounts to 14.54M USD, decreased -5.71 % YoY.

arrow icon

What is Ocular Therapeutix Inc (OCUL)'s earnings per share (EPS) for the last quarter?

Ocular Therapeutix Inc. EPS for the last quarter amounts to -0.38 USD, increased 72.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ocular Therapeutix Inc (OCUL)'s fundamentals?

The market is revising Downward the revenue expectations for Ocular Therapeutix, Inc. (OCUL) for FY2025, with the revenue forecasts being adjusted by -1.65% over the past three months. During the same period, the stock price has changed by -8.60%.
arrow icon

How many employees does Ocular Therapeutix Inc (OCUL). have?

Ocular Therapeutix Inc (OCUL) has 274 emplpoyees as of December 05 2025.

arrow icon

What is Ocular Therapeutix Inc (OCUL) market cap?

Today OCUL has the market capitalization of 2.65B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free